23rd May 2022 20:21
Arecor Therapeutics PLC - Essex, England-based biopharmaceutical company - Says it is making progress with two lead clinical stage programmes focused on diabetes. Says phase one clinical trial data for both lead product, AT247, an ultra-rapid insulin and for second product AT278, a concentrated rapid insulin targeting patients who require higher volumes of insulin, "excelled our expectations". Read More
